Prevalence and Virologic Consequences of HIV-1 Genotype Mutations Detected in a Cohort of 161 Italian Patients Receiving a Nelfinavir-Based Highly Active Antiretroviral Therapy

References

• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatients Study Investigators. N Engl J Med 1998; 338: 853–60.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Squires KE, Hughes MD, et al. A con-trolled trial of two nucleoside analogues plus indinavir in per-sons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter of less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725–33.
   PubMed Web of Science ®Google Scholar
• Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society - USA Panel. JAMA 2000; 283: 381–90.
   Google Scholar
• Kemper CA, Witt MD, Keiser PH, et al. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS 2001; 15: 609–15.
   PubMed Web of Science ®Google Scholar
• Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14: F83–93.
   PubMed Web of Science ®Google Scholar
• Kozal MJ, Shafer RS, Winters MA, Katzenstein DA, Merigan TC. A mutation in HIV reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993; 167: 526–32.
   PubMed Web of Science ®Google Scholar
• Japour AJ, Welles S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995; 171: 1172–9.
   PubMed Web of Science ®Google Scholar
• Pazzani MJ, See D, Schroeder E, Tilles J. Application of an expert system in the management of HIV-infected patients. J Acquir Immune Defic Syndr 1997; 15: 356–62.
   Web of Science ®Google Scholar
• Coffin J. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483–9.
   PubMed Web of Science ®Google Scholar
• Domingo E. RNA virus mutations and fitness for sur-vival. Ann Rev Microbiol 1997; 51: 151–78.
   PubMed Web of Science ®Google Scholar
• Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infec-tion: implications for clinical management. JAMA 1998; 279: 1984–91.
   PubMed Web of Science ®Google Scholar
• Atkinson B, Isaacson J, Knowles M, Mazabel E, Patick AK. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiv-ing nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine. J Infect Dis 2000; 182: 420–7.
   PubMed Web of Science ®Google Scholar
• Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs 2000; 59: 581–620.
   PubMed Web of Science ®Google Scholar
• Saag MS, Tebas P, Sension M, et al. Randomized, double-blind comparison of two nelfinavir doses plus nucleo-sides in HIV-infected patients. AIDS 2001; 15: 1971–8.
   PubMed Web of Science ®Google Scholar
• Puig T, Perez-Olmeda M, Rubio A. Prevalence of geno-typic resistance to nucleoside analogues and protease inhibitors in Spain. AIDS 2000; 14: 727–32.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rosado R, Briones C, Soriano V. Introduction of HIV drug resistance testing in clinical practice. AIDS 1999; 13: 1007–14.
   PubMed Web of Science ®Google Scholar
• Durant J, Clevenbergh P, Halfon P, et al. Drug resis-tance genotyping in HIV-1 therapy: the VIRADAPT ran-domised controlled trial. Lancet 1999; 353: 2195–9.
   PubMed Web of Science ®Google Scholar
• Iversen AK, Shafer RW, Wehrly K, et al. Multidrug-resistant human immunodeficiency virus type 1 strains result-ing from combination antiretroviral therapy. J Virol 1996; 70: 1086-90.
   Google Scholar
• Tamalet C, Yahi N, Tourres C, et al. Multidrug resis-tance genotypes (insertions in the beta3-beta4 finger subdo-main and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations. Virology 2000; 270: 310–6.
   PubMed Web of Science ®Google Scholar
• Re MC, Border M, Monari P, et al. Prevalence of mul-tiple dideoxynucleoside analogue resistance (MddNR) in a cohort of Italian HIV-1 seropositive patients extensively treat-ed with antiretroviral drugs. Int J Antimicrob Ag 2001; 18: 519–23.
   PubMed Web of Science ®Google Scholar
• Yahi N, Tamalet C, Tourres C. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J Clin Microbiol 1999; 37: 4099-106.
   Google Scholar
• Soden D, Hurley A, Zhang L, et al. HIV-1 drug resis-tance in newly infected individuals. JAMA 1999; 282: 1135-41.
   Google Scholar
• Little S, Daar E, D'Aquila R, et al. Reduced antiretrovi-ral drug susceptibility among patients with primary HIV infec-tion. JAMA 1999; 282: 1142–9.
   PubMed Web of Science ®Google Scholar
• Boucher CA, O'Sullivan E, Mulder JW. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165: 105–10.
   PubMed Web of Science ®Google Scholar
• Cleland A, Watson HG, Robertson P, Ludlam CA, Brown AJ. Evolution of zidovudine resistance-associated geno-types in human immunodeficiency virus type 1-infected patients. J Acquir Immune Defic Syndr 1996; 12: 6–18.
   Web of Science ®Google Scholar
• Hooker DJ, Tachedjian G, Solomon AE. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymi-dine. J Virol 1996; 70: 8010–8.
   PubMed Web of Science ®Google Scholar
• Larder BA, Kellam P, Kemp S. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991; 5: 137–44.
   PubMed Web of Science ®Google Scholar
• Pandey VN, Kaushik N, Rege N, Sarafianos SG, Yadav PM, Modak MJ. Role of methionine 184 of human immunod-eficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry 1996; 35: 2168-79.
   Google Scholar
• Van Vaerenbergh K, Van Laethem K, Albert J, et al. Prevalence and chracteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 2000; 44: 2109-17.
   Google Scholar
• Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Nat Acad Sci USA 1995; 92: 2398-402.
   Google Scholar
• Perez-Alvarez L, Villahermosa ML, Cuevas MT, et al. Single and multidrug resistance mutations to reverse transcrip-tase and protease inhibitors: human immunodeficency virus type 1-infected patients from two geographical areas in Spain. Spanish groups for antiretroviral resistance studies. J Hum Virol 2000; 3: 150–6.
   PubMedGoogle Scholar
• Pellegrin I, Izopet J, Reynes J, et al. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naïve patients receiving stavudine plus didanosine combination therapy. STADI group. AIDS 1999; 13: 1705–9.
   Google Scholar
• Balotta C, Violin M, Monno L, et al. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1 infected Italian patients with viro-logic failure. J Acquir Immune Defic Syndr 2000; 24: 232–40.
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Kelly DV, Tsen-g AL, Humar A, Harrigan PR. Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing sal-vage antiretroviral therapy. AIDS 2001; 15: 1581–4.
   PubMed Web of Science ®Google Scholar
• Casado J, Hertogs K, Luiz R. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevi-rapine plus protease inhibitor-containing regimen. AIDS 2000; 14: F1–7.
   PubMed Web of Science ®Google Scholar
• Manfredi R. A cross-sectional survey of HIV genotype mutations conferring resistance to all nonnucleoside reverse transcriptase inhibitors and related features, at the time of fail-ure of antiretroviral therapy in the real world. J Acquir Immune Defic Sindr 2001; 28: 97–9.
   PubMed Web of Science ®Google Scholar
• Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral drug resistant HIV-1 variants. Lancet 1999; 354: 729–33.
   PubMed Web of Science ®Google Scholar
• Roberts NA, Craig JC, Sheldon J. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. AIDS 1998; 12: 453–60.
   PubMed Web of Science ®Google Scholar
• Ives KJ, Jacobsen H, Galpin SA. Emergence of resis-tant variants of HIV in vivo during monotherapy with the pro-tease inhibitor saquinavir. J Antimicrob Chemother 1997; 39: 771–9.
   PubMed Web of Science ®Google Scholar
• Patick AK, Boritzki TJ, Bloom LA. Activity of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse tran-scriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob Agents Chemother 1997; 41: 2159-64.
   Google Scholar
• Patick AK, Duran M, Cao Y, et al. Genotypic and phe-notypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 1998; 42: 2637–44.
   Google Scholar
• Kijak GH, Pampuro SE, Avila MM, et al. Resistance profiles to antiretroviral drugs in HIV-1 drug naïve patients in Argentina. Antiviral Ther 2001; 6: 71–7.
   PubMed Web of Science ®Google Scholar
• Adje C, Cheingsong R, Roels TH, et al. High preva-lence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2001; 26: 501–6.
   PubMed Web of Science ®Google Scholar
• Tamalet C, Pasquier C, Yahi N, et al. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. J Med Virol 2000; 61: 181–6.
   PubMed Web of Science ®Google Scholar
• Fitzgibbon JE, Gaur S, Walsman SM, Janahi M, Whitley-Williams P, John JFJr. Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens. AIDS Res Hum Retrov 2001; 17: 1321–8.
   PubMed Web of Science ®Google Scholar
• Tebas P, Patick AK, Kane EM, et al. Virologic response to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 1999; 13: F23–8.
   Web of Science ®Google Scholar
• Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 1999; 13: F17–21.
   PubMed Web of Science ®Google Scholar
• Yerly S, Rickenbach M, Popescu M, Taffe P, Craig C, Perrin L. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir. Antiviral Ther 2001; 6: 185–9.
   PubMed Web of Science ®Google Scholar